First In Human Study of CX-2051 in Advanced Solid Tumors
The purpose of this first-in-human study, CTMX-2051-101, is to characterize the safety, tolerability, and antitumor activity of CX-2051 in adult subjects with advanced solid tumors.
- EligibilityCriteria: Inclusion Criteria:  Metastatic or locally advanced unresectable solid tumor that has progressed after standard therapy Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 Measurable disease per RECIST v1.1 Consent to fresh biopsy or if medically contraindicated, recent (within 6 months) archival tumor tissue Additional inclusion criteria may apply  Exclusion Criteria:  Recent history (within last 2 years) of localized cancers that are not related to the current cancer being treated Known active central nervous system (CNS) involvement by malignancy Systemic anticancer treatment, radiotherapy, or investigational agent(s) within 14 days prior to C1D1 Previous treatment with antibody-drug conjugates (ADCs) with Topo-I inhibitor payload Major surgery (requiring general anesthesia) within 4 weeks prior to C1D1 Elevated baseline laboratory values Serious concurrent illness Pregnant or breast feeding Additional exclusion criteria may apply - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult